FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma

Imaging in Medicine

Volumn 4, Issue 6, 2012, Pages 633-647

  Paidpally, Vasavi ^a   Chirindel, Alin ^a   Lam, Stella ^a   Agrawal, Nishant ^b   Quon, Harry ^b   Subramaniam, Rathan M ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FDG; head and neck squamous cell carcinoma; imaging biomarkers; PET CT

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FOLLOW UP; GLYCOLYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LARYNX CARCINOMA; MEDICAL DEVICE; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; TONGUE CARCINOMA; TUMOR VOLUME;

EID: 84871215580     PISSN: 17555191     EISSN: 17555205     Source Type: Journal    
DOI: 10.2217/iim.12.60     Document Type: Review

References (80)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J. Nucl. Med. 50(1), 24-29 (2009).
3. Daley T, Darling M. Nonsquamous cell malignant tumours of the oral cavity: an overview. J. Can. Dent. Assoc. 69(9), 577-582 (2003).
4. Imsande HM, Davison JM, Truong MT, et al. Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. AJR Am. J. Roentgenol. 197(4), 976-980 (2011).
5. Moeller BJ, Rana V, Cannon BA, et al. Prospective risk-adjusted [18F] fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J. Clin. Oncol. 27(15), 2509-2515 (2009).
6. Dammann F, Horger M, Mueller-Berg M, et al. Rational diagnosis of squamous cell carcinoma of the head and neck region. comparative evaluation of CT, MRI, and 18FDG PET. AJR Am. J. Roentgenol. 184(4), 1326-1331 (2005).
7. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur. J. Nucl. Med. 25(9), 1255-1260 (1998).
8. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma. comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233(1), 93-100 (2004).
9. Rodrigues RS, Bozza FA, Christian PE, et al. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck. J. Nucl. Med. 50(8), 1205-1213 (2009).
10. Roh JL, Pae KH, Choi SH, et al. 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. European J. Surg. Oncol. 33(6), 790-795 (2007).
11. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2- deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer. An analysis of 125 cases. Leuven Lung Cancer Group. J. Clin. Oncol. 17(10), 3201-3206 (1999).
12. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F] -D-glucose. Cancer 82(11), 2227-2234 (1998).
13. Machtay M, Natwa M, Andrel J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 31(2), 195-201 (2009).
14. Mori M, Tsukuda M, Horiuchi C, et al. Efficacy of fluoro-2-deoxy-D- glucose positron emission tomography to evaluate responses to concurrent chemoradiotherapy for head and neck squamous cell carcinoma. Auris Nasus Larynx 38(6), 724-729 (2011).
15. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J. Nucl. Med. 53(5), 709-715 (2012).
16. Murphy JD, La TH, Chu K, et al. Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 80(2), 514-521 (2011).
17. Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J. Cancer Res. Clin. Oncol. 137(7), 1085-1093 (2011).
18. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose. Int. J. Radiat. Oncol. Biol. Phys. 59(5), 1295-1300 (2004).
19. Lee SW, Nam SY, Im KC, et al. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother. Oncol. 87(2), 211-216 (2008).
20. Xie P, Yue JB, Fu Z, Feng R, Yu JM. Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann. Oncol. 21(5), 1078-1082 (2010).
21. Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[(18)F] fluoro- 2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J. Clin. Oncol. 20(5), 1398-1404 (2002).
22. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, Mcgurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br. J. Cancer 86(4), 512-516 (2002).
23. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J. Nucl. Med. 38(12), 1907-1911 (1997).
24. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am. J. Roentgenol. 195(2), 310-320 (2010).
25. Benz MR, Evilevitch V, Allen-Auerbach MS, et al. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J. Nucl. Med. 49(7), 1038-1046 (2008).
26. Jackson T, Chung MK, Mercier G, Ozonoff A, Subramaniam RM. FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site. Nucl. Med. Commun. 33(3), 305-312 (2012).
27. Krabbe CA, Pruim J, Dijkstra PU, Roodenburg JL. 18F-FDG PET for routine posttreatment surveillance in oral and oropharyngeal squamous cell carcinoma. J. Nucl. Med. 51(7), 1164; author reply 1164-1165 (2010).
28. Kubicek GJ, Champ C, Fogh S, et al. FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol. 2, 19 (2010).
29. Liao CT, Chang JT, Wang HM, et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int. J. Radiat. Oncol. Biol. Phys. 73(3), 764-771 (2009).
30. Torizuka T, Tanizaki Y, Kanno T, et al. Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am. J. Roentgenol. 192(4), W156-W160 (2009).
31. Greven KM, Williams DW 3rd, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23(11), 942-946 (2001).
32. Vernon MR, Maheshwari M, Schultz CJ, et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 70(3), 678-684 (2008).
33. Zhang B, Li X, Lu X. Standardized uptake value is of prognostic value for outcome in head and neck squamous cell carcinoma. Acta Otolaryngol. 130(7), 756-762 (2010).
34. Kim SY, Roh JL, Kim MR, et al. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J. Nucl. Med. 48(5), 752-757 (2007).
35. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]- fluorodeoxyglucose and positron emission tomography. review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group. Eur. J. Cancer 35(13), 1773-1782 (1999).
36. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med. 50(Suppl. 1), 122S-150S (2009).
37. Han MW, Ryu IS, Lee SW, et al. Can response to induction chemotherapy be a predictive marker for ultimate outcome in hypopharyngeal cancer? Otolaryngol. Head Neck Surg. 146(1), 74-80 (2012).
38. McCollum AD, Burrell SC, Haddad RI, et al. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck 26(10), 890-896 (2004).
39. Yoon DH, Cho Y, Kim SY, et al. Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 81(1), 118-125 (2011).
40. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J. Clin. Oncol. 23(33), 8362-8370 (2005).
41. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer. prediction of response to chemotherapy by quantitative assessment of glucose use. J. Clin. Oncol. 21(14), 2651-2657 (2003).
42. Ishihara R, Yamamoto S, Iishi H, et al. Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography. toward PET-response-guided selection of chemoradiotherapy or esophagectomy. Int. J. Clin. Oncol. 17(3), 225-232 (2012).
43. Chepeha DB, Sacco AG, Oxford LE, et al. Advanced squamous cell carcinoma of the oropharynx: efficacy of positron emission tomography and computed tomography for determining primary tumor response during induction chemotherapy. Head Neck 31(4), 452-460 (2009).
44. Hentschel M, Appold S, Schreiber A, et al. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur. J. Nucl. Med. Mol. Imag. 38(7), 1203-1211 (2011).
45. Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment. prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24(2), 127-135 (2002).
46. Yen TC, Lin CY, Wang HM, et al. 18F-FDG-PET for evaluation of the response to concurrent chemoradiation therapy with intensity-modulated radiation technique for Stage T4 nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 65(5), 1307-1314 (2006).
47. Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck 19(8), 666-674 (1997).
48. Connell CA, Corry J, Milner AD, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 29(11), 986-995 (2007).
49. Ceulemans G, Voordeckers M, Farrag A, Verdries D, Storme G, Everaert H. Can 18-FDG-PET during radiotherapy replace post-therapy scanning for detection/demonstration of tumor response in head-and-neck cancer? Int. J. Radiat. Oncol. Biol. Phys. 81(4), 938-942 (2011).
50. Kitagawa Y, Sadato N, Azuma H, et al. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J. Nucl. Med. 40(7), 1132-1137 (1999).
51. Sherriff JM, Ogunremi B, Colley S, Sanghera P, Hartley A. The role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy. Br. J. Radiol. 85(1019), e1120-e1126 (2012).
52. Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer. a systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imag. 38(11), 2083-2095 (2011).
53. Kao J, Vu HL, Genden EM, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer 115(19), 4586-4594 (2009).
54. Yao M, Smith RB, Hoffman HT, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int. J. Radiat. Oncol. Biol. Phys. 74(1), 9-14 (2009).
55. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [(18)F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 20(20), 4199-4208 (2002).
56. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 110(3 Pt 2 Suppl. 93), 1-18 (2000).
57. Lucignani G. SUV and segmentation: pressing challenges in tumour assessment and treatment. Eur. J. Nucl. Med. Mol. Imag. 36(4), 715-720 (2009).
58. Higgins KA, Hoang JK, Roach MC, et al. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer. tumor SUVmean has superior prognostic value. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 548-553 (2012).
59. Lodge MA, Chaudhry MA, Wahl RL. Noise Considerations for PET quantification using maximum and peak standardized uptake value. J. Nucl. Med. 53(7), 1041-1047 (2012).
60. Chung MK, Jeong HS, Park SG, et al. Metabolic tumor volume of [18F]- fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin. Cancer Res. 15(18), 5861-5868 (2009).
61. Romesser PB, Qureshi MM, Shah BA, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann. Nucl. Med. 26(7), 527-534 (2012).
62. Jayachandran P, Pai RK, Quon A, et al. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 4(2), 471-477 (2012).
63. Lee P, Bazan JG, Lavori PW, et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. Clin. Lung Cancer 13(1), 52-58 (2012).
64. Song MK, Chung JS, Shin HJ, et al. Prognostic value of metabolic tumor volume on PET /CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci. 103(3), 477-482 (2012).
65. La TH, Filion EJ, Turnbull BB, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 74(5), 1335-1341 (2009).
66. Tang C, Murphy JD, Khong B, et al. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 83(5), 1514-1520 (2012).
67. Chu KP, Murphy JD, La TH, et al. Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. Int. J. Radiat. Oncol. Biol. Phys. 83(5), 1521-1527 (2012).
68. Hatt M, Visvikis D, Pradier O, Cheze-Le Rest C. Baseline (1)(8)F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer. Eur. J. Nucl. Med. Mol. Imag. 38(9), 1595-1606 (2011).
69. Erdi YE, Macapinlac H, Rosenzweig KE, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur. J. Nucl. Med. 27(7), 861-866 (2000).
70. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 247(1), 189-196 (2008).
71. Gu J, Khong PL, Wang S, Chan Q, Law W, Zhang J. Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT. Mol. Imag. Biol. 13(5), 1020-1028 (2011).
72. Manohar K, Mittal BR, Bhattacharya A, Malhotra P, Varma S. Prognostic value of quantitative parameters derived on initial staging 18F- fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma. Nucl. Med. Commun. 33(9), 974-981 (2012).
73. Chan SC, Chang JT, Lin CY, et al. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl. Med. Commun. 32(11), 989-996 (2011).
74. Chang KP, Tsang NM, Liao CT, et al. Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma. J. Nucl. Med. 53(1), 21-28 (2012).
75. Moon SH, Choi JY, Lee HJ, et al. Prognostic value of (18) F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil. Comparisons of volume-based metabolic parameters. Head Neck doi:10.1002/hed.22904 (2012) (Epub ahead of print).
76. Cheng NM, Chang JT, Huang CG, et al. Prognostic value of pretreatment (18)F-FDG PET/CT and human papillomavirus type 16 testing in locally advanced oropharyngeal squamous cell carcinoma. Eur. J. Nucl. Med. Mol. Imag. 39(11), 1673-1684 (2012).
77. De Langen AJ, Vincent A, Velasquez LM, et al. Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J. Nucl. Med. 53(5), 701-708 (2012).
78. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl. Med. Biol. 27(7), 643-646 (2000).
79. Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J. Nucl. Med. 45(5), 784-788 (2004).
80. Berghmans T, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J. Thorac. Oncol. 3(1), 6-12 (2008).